ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HSK50042

A development code. Also written as “HSK50042 dose 1”, “HSK50042 dose 2” and “HSK50042 dose 3”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Haisco Pharmaceutical Group.

Furthest: phase 2, since Jul 22, 20261 company-led study, 1 open or runningNext primary completion: Apr 10, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group11 open or runningphase 2since Jul 22, 2026Jul 22, 2026Apr 10, 2028phase 2 · NCT07728721

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 22, 2026First study: phase 2 study in Idiopathic Pulmonary FibrosisFirst studyNCT07728721 · 175 planned

Ahead

  1. Apr 10, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07728721

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07728721Idiopathic Pulmonary Fibrosis2Not yet recruitingApr 10, 2028175

How it is read

Names in the registry

  • “HSK50042 dose 1”, 1 entry
  • “HSK50042 dose 2”, 1 entry
  • “HSK50042 dose 3”, 1 entry

Codes read as this program: HSK50042.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.